Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and ... Fort Mills Times Emergent BioSolutions Inc. (NYSE: EBS) today announced its decision to expand the protocol for its ongoing Phase 1b, single arm, open label study (Protocol 16009) evaluating the safety and efficacy of TRU-016 in combination with rituximab in previously ... |
